Navigation Links
Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohn's Disease
Date:8/19/2011

CAMBRIDGE, Mass., Aug. 19, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA) technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn's disease.   The precise measurement of low abundance cytokines, which was possible using Quanterix's high sensitivity digital ELISA, allowed significant changes to be detected in patients before and after initiation of therapy.  The study was published online in the Journal of Immunological Methods.

"Quanterix's digital ELISA enabled physiologically relevant concentrations of two important cytokines, TNF-alpha and IL-6, to be measured in plasma from all patient samples tested.  Previous studies have not been able to quantify these biomarkers in all patients due to insufficient sensitivity," explained David Duffy, Ph.D., corresponding author of the study.  "The inherent sensitivity of this technology also made it possible, for the first time, to accurately quantify changes in protein levels during the course of anti-TNF-alpha therapy.  This work has important implications for patient management, including the ability to provide a quantitative index for how an individual is responding to therapy."

"Our collaboration with the Mayo Clinic is another example that highlights how unprecedented sensitivity enables important contributions to life science research and in vitro diagnostics," said Martin Madaus, Ph.D., Quanterix Executive Chairman.  "Although larger studies will be needed to fully understand the potential utility of cytokine measurements in the diagnosis of inflammatory diseases such as Crohn's, these results provide some indication of how sensitive and precise protein measurements enabled by SiMoA could be used clinically."

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix and STRATEC Announce Strategic Partnership
2. Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
3. Quanterix Announces New Technology Evaluation Agreement
4. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
5. COPAN Announces Workshop on Automated Specimen Processing, Digital Workup and Reporting in Microbiology During AACC Clinical Lab Expo
6. Volcano Announces the Introduction of the Eagle Eye® Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki
7. QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital™ PCR Platform and Establish Commercial Operations by 2011
8. Virginia Tech, Carilion team with physician to create digital ER pediatric response chart
9. QuantaLife Announces Launch of Droplet Digital™ PCR System
10. Skin & Allergy News Digital Network Launches Product Zone
11. Viscira Delivers Key Presentation to Pharmaceutical Marketing Professionals at Leading Digital Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... BEACH, Florida , February 16, 2017 /PRNewswire/ ... improving with the infusion of innovative telemedicine application, ... monitoring services that are experiencing a boom worldwide. ... with the advancement of technologies, services and new ... Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, today ... 1a financing and entered into a $5 million ... intends to use the capital for general corporate ... advancements in the treatment of serious diseases treated ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 /PRNewswire/ ... point. Driven largely by the confluence of organizations, ... users, distaste for knowledge-based systems (password and challenge ... consumer, industrial, and government systems. The market is ... been a demarcation between consumer and enterprise uses ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):